Dave Amerson - President and CEO, NeoTract, Inc.
Dave is President and CEO of NeoTract, Inc., a medical device company dedicated to developing innovative, clinically effective solutions that address unmet needs in the field of urology.
received FDA De Novo approval in September 2013 to market the UroLift® System, a minimally invasive technology to treat symptoms of benign prostatic hyperplasia (BPH), in the U.S.
has also led the company to achieve important OUS commercial milestones, including positive NICE guidance for the UroLift system in the UK and a prosthesis code with payment for the UroLift implant in Australia.
Dave joined NeoTract in July 2011, bringing over 25 years of management experience in the medical device field with an emphasis in urology.
Prior to NeoTract, Dave was Global Vice President, General Manager for the Coloplast Surgical Urology division.
In this role, he
was responsible for Sales, Marketing, Quality/Regulatory, R&D, Clinical Studies, Manufacturing and Legal.
In 2006, Dave
was the point person for the divestiture of Mentor's urology business unit that was acquired by Coloplast Corporation
Post-acquisition, Dave led the Global Surgical Urology division at Coloplast to achieve double digit sales growth and launch several innovative new products.
Dave began his career at Osbon Medical Systems where he built a successful sales and marketing team that achieved aggressive sales growth.
Osbon Medical was acquired by Urohealth Systems, Inc. in 1995.
Dave is a former board member of the Urology Society of America, the American Lithotripsy Society and EMKinetics.
Dave holds an M.B.A. from Argosy University and a B.A. in Political Science from the University of West Georgia.